华北制药
(600812)
| 流通市值：80.12亿 | | | 总市值：80.12亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,153,167,876.49 | 9,241,652,953.8 | 7,484,828,636.64 | 5,275,037,790.2 |
| 营业收入 | 2,153,167,876.49 | 9,241,652,953.8 | 7,484,828,636.64 | 5,275,037,790.2 |
| 二、营业总成本 | 2,088,645,071.89 | 8,957,348,085.02 | 7,258,017,573.93 | 5,064,452,841.41 |
| 营业成本 | 1,529,816,825.63 | 6,376,291,487.83 | 5,295,459,714.07 | 3,712,471,185.76 |
| 税金及附加 | 28,033,926.51 | 108,781,473.4 | 81,610,453.98 | 58,901,920.86 |
| 销售费用 | 221,664,872.41 | 1,231,089,983.18 | 969,584,616.21 | 682,307,914.65 |
| 管理费用 | 132,557,417.81 | 554,117,130.38 | 395,365,377.85 | 264,978,738.01 |
| 研发费用 | 95,623,753.58 | 340,998,836.39 | 253,811,956.49 | 169,073,874.09 |
| 财务费用 | 80,948,275.95 | 346,069,173.84 | 262,185,455.33 | 176,719,208.04 |
| 其中:利息费用 | 74,988,313.19 | 361,548,158.82 | 276,486,185.63 | 190,640,852.41 |
| 其中:利息收入 | 4,623,296.58 | 25,816,694.2 | 16,631,110.47 | 13,034,013.73 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 14,639,070.57 | 60,625,000.37 | 42,102,545.14 | 26,285,765.54 |
| 资产处置收益 | 20,894.61 | 827,335.68 | 759,717.4 | -9,846.67 |
| 资产减值损失(新) | -265,870.11 | 17,226,881.24 | 28,637,601.76 | 7,432,452.04 |
| 信用减值损失(新) | -17,576,736.4 | -44,196,286.29 | -34,909,777.16 | -38,886,024.62 |
| 其他收益 | 5,234,624.23 | 35,183,803.6 | 23,503,062.51 | 8,366,394.1 |
| 四、营业利润 | 66,574,787.5 | 353,971,603.38 | 286,904,212.36 | 213,773,689.18 |
| 加:营业外收入 | 59,589.24 | 4,953,011.43 | 1,067,182.69 | 633,098.54 |
| 减:营业外支出 | 353,172.97 | 1,515,666.77 | 755,839.43 | 370,543.27 |
| 五、利润总额 | 66,281,203.77 | 357,408,948.04 | 287,215,555.62 | 214,036,244.45 |
| 减:所得税费用 | 16,904,320.58 | 99,955,846.2 | 75,676,686.45 | 51,749,387.85 |
| 六、净利润 | 49,376,883.19 | 257,453,101.84 | 211,538,869.17 | 162,286,856.6 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 49,376,883.19 | 257,453,101.84 | 211,538,869.17 | 162,286,856.6 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 35,472,827.49 | 183,056,160.84 | 158,504,018.75 | 123,497,402.89 |
| 少数股东损益 | 13,904,055.7 | 74,396,941 | 53,034,850.42 | 38,789,453.71 |
| 扣除非经常损益后的净利润 | 32,264,176.51 | 165,918,468.01 | 143,324,253 | 119,946,433.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.11 | 0.09 | 0.07 |
| (二)稀释每股收益 | 0.02 | 0.11 | 0.09 | 0.07 |
| 八、其他综合收益 | -1,662,299.38 | -14,247,723.02 | -209,831.87 | -412,469.02 |
| 归属于母公司股东的其他综合收益 | -1,662,299.38 | -14,247,723.02 | -209,831.87 | -412,469.02 |
| 九、综合收益总额 | 47,714,583.81 | 243,205,378.82 | 211,329,037.3 | 161,874,387.58 |
| 归属于母公司股东的综合收益总额 | 33,810,528.11 | 168,808,437.82 | 158,294,186.88 | 123,084,933.87 |
| 归属于少数股东的综合收益总额 | 13,904,055.7 | 74,396,941 | 53,034,850.42 | 38,789,453.71 |
| 公告日期 | 2026-04-25 | 2026-04-18 | 2025-10-25 | 2025-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |